Overview of the drug development pipeline for Tourette syndrome
It has been observed that Tourette syndrome is a neurological disorder that is characterized by repetitive, sudden, and involuntary movements or noises called tics due to the mutations of the SLITRK1 gene. SLITRK1 plays an important role in the development of nerve cells. It involves four types of tics, namely motor tics (uncontrolled body movements), vocal tics (outburst of sound), simple tics (involves few parts of the body), and complex tics (involves several parts of the body).
The symptoms of Tourette syndrome put people at the risk of developing attention deficit/hyperactivity disorder (ADHD), obsessive compulsive disorder (OCD), anxiety, depression, and sleep-related problems. It starts between the age of 3 and 9, and it spreads over a period. According to the National Institutes of Health (NIH), it is estimated that 1 to 10 in 1,000 children are affected by the symptoms of Tourette syndrome globally. Several public and private companies are focused on the development of drug molecules for the treatment of Tourette syndrome. Monotherapy is emerging as the most efficient approach for the treatment of Tourette syndrome.
According to this pipeline analysis report, all the drug molecules in the pipeline are being developed for the treatment of Tourette syndrome. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
Pipeline analysis report on drug development for Tourette syndrome: Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of Tourette syndrome. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are
- Abide Therapeutics
- Catalyst Pharma
- Kempharm
Therapeutic assessment of the drug development pipeline for Tourette syndrome by route of administration
- Oral
- Transdermal
- Unknown
The oral route of administration (ROA) involves the administration of the drug directly into the mouth cavity, which will have a more direct effect on the target cells.
Therapeutic assessment of the drug development pipeline for Tourette syndrome by therapy
- Monotherapy
- Combination Therapy
- Unknown
According to this pipeline analysis report, most of the molecules that are currently in the drug pipeline Tourette syndrome are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Key questions answered in the report include
- What are the drug therapy molecules in the various development stages for Tourette syndrome?
- What are the companies that are currently involved in the development of drug molecules for Tourette syndrome?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.